What is the main business of Biovena Health?

The main business activity of Biovena Health focuses on manufacture of pharmaceutical preparations.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on November 14, 2006.

Where is the headquarters located?

The headquarters is located at: ul. Kolejowa 49, 05-092 Łomianki.

What is the share capital?

The share capital of the company is PLN 300,000 (approx. $81,037).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What revenue was generated?

The company reported a revenue of USD 6,016,231 in 2025, which is an increase of 18.7% compared to 2024.

Is the company profitable?

Yes, the company recorded a net profit of USD 895,213 in 2025, meaning the company decreased its profit by 11.2%.

What is the main operating cost?

The largest operating cost category falls under external services. This category amounted to USD 2,050,242 in 2025, representing 41% of all operating expenses.

Biovena Healthsp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2006-11-14

Share capital

300,000.00 PLN

Activity description

Biovena Health is a Polish company that has designed and manufactured certified medical devices, dietary supplements and pharmacy cosmetics for 20 years. Its portfolio includes more than 70 products and 13 own brands, including tick and mosquito preparations, silicone scar plasters, home diagnostics and medical equipment. The company also offers Multizum HA, a sterile hyaluronic acid solution for intravesical instillations, and works with pharmacies, wholesalers and distributors in Poland and abroad.

Registered address

ul. Kolejowa 49, 05-092 Łomianki, Poland

Website

biovenahealth.com

Opening hours

Monday–Friday: 9:00–17:00

Phone

Financials

Revenue history (in k)

Financial insight

Estonian CIT: Equity includes non-zero Art. 28d line items – the company is taxed under the lump-sum regime on corporate income.

Filing timeliness

1 of 6 financial statements was filed late (for 2021, 90 days late).

202518/06/2026
202410/07/2025
202315/05/2024
202215/07/2023
202113/10/2022
202019/05/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 6.02mMedianUSD 917.74kAverageUSD 25.73m

Net profit

This companyUSD 895.21kMedianUSD 14.44kAverageUSD 2.75m

Operating costs

This companyUSD 4.99mMedianUSD 860.03kAverageUSD 21.34m

Assets

This companyUSD 4.03mMedianUSD 883.09kAverageUSD 31.39m

Industry

Offer

Dietary supplements
Pharmacy cosmetics
Biocidal products
Medical devices
Medical equipment
Thermometers
Diagnostic tests

Public procurement

Biovena Health is the contractor in one public sector contract, worth USD 6.26k.

Signed on	Subject	Amount	Public buyer
Jul 30, 2026	Uroflowmeter – 1 set	$6,257	Uniwersyteckie Centrum Kliniczne

Trademarks

Biovena Health holds 34 active trademarks registered with the Polish Patent Office. 2 applications are pending. 10 marks have expired or were not registered. The first mark was filed in 2006.

Mark	Number	Classes	Status	Protected until
QUEREA(word)	Z.596829	5	Protected	Jan 20, 2036
PROCTIVA(word)	Z.596827	5	Protected	Jan 20, 2036
Vena Bloom(word)	Z.586825	3, 5	Protected	Jun 30, 2035
Vena Glow(word)	Z.586854	3, 5	Protected	Jun 30, 2035
ANUFLOR(word)	Z.580495	5	Protected	Feb 14, 2035

Mark	Protected until
QUEREA(word)	Jan 20, 2036
PROCTIVA(word)	Jan 20, 2036
Vena Bloom(word)	Jun 30, 2035
Vena Glow(word)	Jun 30, 2035
ANUFLOR(word)	Feb 14, 2035

Authorized Representatives

Daniel Woźniak – President of the Management Board

Manner of representation

Each member of the management board is authorised to make declarations on behalf of the company independently.

Ownership

Owner	Shares	Share value	Stake
Daniel Paweł Woźniakage 51	600	$81,037.28	100%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2006-11-13.

Alior Bank
35 2490 0005 0000 4520 5376 5228
Bank Pekao SA
41 1240 1040 1111 0010 9602 8367
Alior Bank
67 2490 0005 0000 4612 1792 1520

Debt

No entries in the National Debtors Register (KRZ).

Real estate

Type	Amount
Land (incl. perpetual usufruct)	$330.9K$330,881
Buildings and premises	$932.4K$932,402

Public aid

11 public aid cases recorded, with a total value of $107,614.

Grant date	Purpose	Gross amount	Granting body
Apr 25, 2025	De minimis aid (in accordance with Commission Regulation 2023/2831)	––	Prezes Banku Gospodarstwa Krajowego
Jun 14, 2023	De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)	––	Prezes Banku Gospodarstwa Krajowego
Jan 14, 2021	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	––	Bank Polska Kasa Opieki S.A.

Regulatory authorisations

Authority	Type	Status
BDO	BDO register entry	Active

Competitors

Name	Revenue	Website
Instytut Biotechnologii Surowic i Szczepionek Biomed - Skrót Firmy Ibss BiomedS.A.	$40,633,950.51	biomed.pl
Poznańskie Zakłady Zielarskie HerbapolS.A.	$31,668,225.77	herbapol.poznan.pl
Fagronsp. z o.o.	$21,715,187.73	fagron.pl
Przedsiębiorstwo Farmaceutyczne Farmapolsp. z o.o.	$21,462,728.43	farmapol.pl
Biofaktorsp. z o.o.	$10,761,755.73	biofaktor.pl
Uropharmasp. z o.o.	$1,113,812.65	uroplus.pl
Natur DayS.A.	$680,635.59	naturday.pl

Change history

Date	Event
2024-01-24	Address change (Odrowąża 15, 03-310, Warszawa → Ul. Kolejowa 49, 05-092, Łomianki)
2018-01-31	Share capital increase (50,000.00 PLN → 300,000.00 PLN)
2015-03-05	Name change (Verco Trade → Biovena Health)
2015-03-05	PKD change (Removed: 53 codes)
2013-06-27	Name change (Tdm Farma → Verco Trade)

FAQ

Last updated: 2026-10-07